EGFR and non-small cell lung carcinoma: Molecular targeted drugs have been developed continuously and the covered fraction of driver mutations among NSCLC patient populations will increase [e.g., EGFR exon 20 insertions, neuregulin 1 (NRG1), human epidermal growth factor receptor 2 (HER2), etc.].